FDA Approves Abatacept to Prevent Graft Versus Host Disease
In December 2021, the U.S. Food and Drug Administration approved abatacept for the prevention of acute graft versus host disease (GVHD), in combination with immunosuppressants. This is the first drug approved for this purpose.
Abatacept, marketed under the name Orencia, may be used in adults and children age 2 or older who are undergoing bone marrow transplants or stem cell transplants from an unrelated donor. Trials and data reviews produced the following results for the use of abatacept in combination with immunosuppressants: Code:
Abatacept Placebo Unrelated-donor transplant comparison The FDA reports that the most common side effects of abatacept include anemia, hypertension, cytomegalovirus infection, fever, pneumonia, nosebleed, decreased levels of certain lymphocytes, increased magnesium level, and acute kidney injury. |
All times are GMT -4. The time now is 10:00 AM. |
Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org